Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Toxicity: Allergic Reactions01:30

Drug Toxicity: Allergic Reactions

173
Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial...
173
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

197
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
197
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

376
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
376
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

712
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
712
Drug Toxicity: Dose-Dependent Reactions01:24

Drug Toxicity: Dose-Dependent Reactions

208
Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
208
Drug Toxicity: Overview01:00

Drug Toxicity: Overview

247
Drug toxicity quantifies the harm a compound causes to an organism, varying by dose and potentially impacting whole systems or specific organs like the liver. Toxic reactions may arise from venomous insect or spider bites, with effects ranging from mild symptoms to severe outcomes such as brain damage or death. Common forms of acute poisoning include ethanol intoxication and overdose of pain or fever medications, with substances like GHB and heroin being particularly lethal at doses close to...
247

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neoadjuvant immunotherapy for resectable cutaneous melanoma: a nationwide population-based cohort.

Journal of the National Cancer Institute·2026
Same author

Immune checkpoint inhibitor therapy after tumor-infiltrating lymphocytes in unresectable melanoma.

Journal for immunotherapy of cancer·2026
Same author

Corrigendum to "Long-term real-world survival outcomes with dual immune checkpoint blockade in synchronous metastatic renal cell carcinoma: implications for the design of prospective cytoreductive nephrectomy trials" [Eur. Urol. Open Sci. 83 (2026) 133-141].

European urology open science·2026
Same author

AI-based histopathology analysis predicts checkpoint inhibitor response in advanced melanoma and identifies patterns associated with response.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Explainable machine learning identifies features and thresholds predictive of immunotherapy response.

Scientific reports·2026
Same author

Local immunotherapy in the neoadjuvant treatment of cancer: optimizing efficacy while limiting toxicity?

Journal for immunotherapy of cancer·2026

Related Experiment Video

Updated: Apr 12, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.3K

Toxicity patterns with immunomodulating antibodies and their combinations.

John B A G Haanen1, Hans van Thienen1, Christian U Blank1

  • 1Division of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.

Seminars in Oncology
|May 13, 2015
PubMed
Summary
This summary is machine-generated.

Immune checkpoint inhibitors like CTLA-4 and PD-1 block self-tolerance, enhancing anti-tumor immunity but causing autoimmune side effects. Immunosuppressive drugs effectively manage these immune-related adverse reactions.

More Related Videos

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation
10:35

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation

Published on: December 26, 2017

8.8K
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

13.0K

Related Experiment Videos

Last Updated: Apr 12, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.3K
Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation
10:35

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation

Published on: December 26, 2017

8.8K
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

13.0K

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Immune checkpoint molecules, including cytotoxic T-lymphocyte antigen-4 (CTLA-4), programmed death-1 (PD-1), LAG-3, and TIM-3, are crucial for maintaining peripheral tolerance and preventing autoimmunity.
  • Antibody-mediated blockade of these immune checkpoints unleashes potent anti-tumor immunity.

Purpose of the Study:

  • To review the toxicity patterns associated with immune checkpoint blockade therapies.
  • To describe adverse events resulting from both single-agent and combination immune checkpoint inhibitor treatments.

Main Methods:

  • Literature review of immune checkpoint blockade therapies.
  • Analysis of immune-related adverse reactions (irAEs) observed in clinical settings.

Main Results:

  • Immune checkpoint blockade, while effective against cancer, frequently leads to irAEs that mimic autoimmune diseases.
  • Combination therapies may present distinct or amplified toxicity profiles compared to single agents.

Conclusions:

  • Understanding toxicity patterns is essential for managing patients undergoing immune checkpoint blockade.
  • Prompt treatment with immunosuppressive drugs is effective in resolving irAEs and their associated symptoms.